The global healthcare problem faced by Alzheimer’s disease (AD), which is characterized by progressive cognitive decline, memory loss, and behavioral abnormalities, has never been more pressing. With an aging population, the prevalence of Alzheimer’s disease is increasing, making it a key point for healthcare innovation.
Eli Lilly’s global head of external engagement for Alzheimer’s disease, Phyllis Barkman-Ferrell, underlines the importance of this issue, noting that “10,000 Baby Boomers turn 65 every day” in the United States alone.
Alzheimer’s disease will affect 13 million Americans by 2050, up from 6 million in 2023. Also, the financial burden in the United States is tremendous, expected to exceed $345 billion in 2023 and surpass $1 trillion by 2050.
Aside from these statistics, Alzheimer’s disease inflicts a socio-emotional toll on patients, caregivers, and families, seeking immediate attention and novel approaches.
The difficulties of dealing with Alzheimer’s disease are exacerbated by a lack of proper medical resources. The Alzheimer’s Association identified the direct care workforce as a critical pillar, emphasizing the need for focused interventions to support patients and caregivers.
Despite a history of drug development failures in the field, recent work provides reason for optimism, showing a possible therapeutic arsenal to limit disease progression at an early stage. While these advances do not provide a cure, they do represent a paradigm shift, highlighting the importance of health technology in patient identification, early diagnosis, disease monitoring, and everyday support for patients and caregivers.
Aptar Digital Health‘s white paper intends to shed light on the issues and pain points experienced by anyone afflicted by Alzheimer’s disease. They look at digital interventions that can help with these issues and discuss the potential benefits of digital health solutions in the Alzheimer’s area.
Aptar Digital Health is dedicated to contributing to this revolutionary landscape by improving the lives of those affected by Alzheimer’s disease.